Smartleaf Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Smartleaf Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.14K	Buy	+59	New	+$6.12K	﹤0.01%	2701

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Smartleaf Asset Management's DNTH Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Dianthus Therapeutics (DNTH) in Q3 2026: 59 shares worth $5.14K. The stake represents ﹤0.01% of the portfolio and ranks #2701 among its holdings.

188 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Smartleaf Asset Management held 59 shares of Dianthus Therapeutics worth $5.14K as of Q3 2026.
Dianthus Therapeutics was a new Smartleaf Asset Management position in Q3 2026.
Dianthus Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2701 holding.
188 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.